INS and type 1 diabetes mellitus: The NewLira study indicated that liraglutide 1.8 mg, administered for 52 weeks, preserved insulin secretion in adults with newly diagnosed T1D, as shown by sustained stimulated C-peptide secretion and lower insulin requirements when compared to placebo [66].